Monday, August 7, the World Health Organization is working with China on requirements for international approval of any Chinese COVID-19 vaccine.
In a briefing in Geneva, Assistant Director-General Mariangela Simao, “WHO office in China and WHO headquarters has been working with the regulatory authorities in China.”
“We are in direct contact, we have been sharing information and the requirements for international approval of vaccines,” she added.
Sinovac Biotech said its coronavirus vaccine candidate appeared to be safe for older people, according to preliminary results from an early to mid-stage trial, while immune responses triggered by the vaccine were slightly weaker than younger adults.
The chief executive of Sinovac Biotech Ltd said on Sunday about 90% of the Chinese firm’s employees and their families have taken an experimental vaccine it has developed under the country’s emergency use program.
The extent of inoculations under the emergency program, which China launched in July but has released few details about, points to how actively it is using experimental vaccines in the hopes of protecting essential workers against a potential COVID-19 resurgence, even as trials are still underway.
Sinovac’s candidate CoronaVac did not cause severe side effects in a combined Phase 1 and Phase 2 trials launched in May involving 421 participants aged at least 60, Liu Peicheng, Sinovac’s media representative, told Reuters.